News | October 30, 2014

Largest Clinical Experience on the Convergent Procedure Presented

Two hundred twenty-four patients treated for atrial fibrillation with 93 percent in sinus rhythm at one-year follow-up

October 30, 2014 — New physician experience for the Convergent Procedure in the treatment of persistent atrial fibrillation (AF) was presented during a podium talk at the Northeast Cardiothoracic Surgical Society 20th Annual Meeting held in East Madison, N.H. William M. Boedefeld II, M.D., of CVT Surgical Center in Baton Rouge, La., reported on 224 patients, 66 percent of whom had persistent or longstanding persistent AF and 34 percent who had paroxysmal AF. At one-year follow-up, 93 percent of patients were in sinus rhythm.

"The Convergent Procedure is our first-line treatment for AF patients with enlarged atria," stated Boedefeld. "For patients with enlarged atria where we may anticipate a second procedure with traditional catheter ablation, even in paroxysmal AF patients, we see the Convergent Procedure as the best opportunity for single-procedure results. The key clinical advantage is the ability to electrically silence the heart's posterior wall, where the majority of AF triggers are known to reside. We achieve this through a minimally invasive procedure, under direct visibility. Our electrophysiology partners can then complete the procedure in the same EP lab setting — our average total procedure time is 3.95 hours."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist ensure lesion set completeness, and specialized EP mapping and diagnostics provide the checks and balances to ensure a comprehensive approach.

"The Convergent Procedure addresses the progressive nature of AF," said Kenneth C. Civello Jr., M.D., MPH, of Our Lady of the Lake Regional Medical Center in Baton Rouge, La. "Standardized, comprehensive ablation of the posterior wall can result in reverse remodeling where the overall atrial volume can be reduced, and function can improve. This allows us to use the Convergent Procedure for all patients with enlarged atria. Patients can then be provided customized care within a long-term disease management program."

For more information: www.fmolhs.org/ololrmc

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init